Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib in ROS1-Translocated Cancers (MATCH Subprotocol G)
NCT04439253Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2015
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of crizotinib in malignant solid neoplasm, lymphoma, multiple myeloma (MM), sponsored by National Cancer Institute. Started Aug 2015; status: active, not recruiting.
02
Drugs
crizotinib
03
Conditions
malignant solid neoplasmlymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT04439253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04439253.